EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer

Patrick M Boland iD, John M L Ebos, Kristopher Attwood, Michalis Mastri, Christos Fountzilas, Renuka V Iyer, Christopher Banker, Andrew K L Goey, Robert Bies, Wen Wee Ma, Marwan Fakih iD

JNCI Cancer Spectrum · 30.04.2024 · 8 (3)

DOI: 10.1093/jncics/pkae017 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 03.05.2024. Verfasst von Patrick M Boland und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Capecitabine, Indoles, Progression-Free Survival, Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Comprehensive Cancer Network, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nintedanib is a tyrosine kinase inhibitor with efficacy in bevacizumab-resistant colorectal cancer models. This phase I/II study evaluated the recommended phase II dose and efficacy of nintedanib and capecitabine in refractory metastatic colorectal cancer.

Methods

Key eligibility criteria included refractory metastatic colorectal cancer and ECOG performance status of 1 or lower. The primary endpoint was 18-week progression-free survival (PFS). A 1-sided binomial test (at α = .1) compared the observed 18-week PFS with a historic control of .25.

Results

Forty-two patients were enrolled, including 39 at the recommended phase II dose. The recommended phase II dose was established to be nintedanib 200 mg by mouth twice daily and capecitabine 1000 mg/m2 by mouth twice daily. The protocol was evaluated for efficacy in 36 patients. The 18-week PFS was 42% (15/36 patients; P = .0209). Median PFS was 3.4 mo. Median overall survival was 8.9 mo. Sixteen (44%) patients experienced a grade 3/4 adverse event, most commonly fatigue (8%), palmoplantar erythrodysesthesia (8%), aspartate aminotransferase elevation (6%), asthenia (6%), pulmonary embolus (6%), and dehydration (6%). Osteopontin levels at cycle 1, day 1 and cycle 3, day 1 as well as ΔCCL2 levels correlated to disease control at 18 weeks.

Conclusions

The combination of nintedanib and capecitabine is well tolerated. Clinical efficacy appears to be superior to regorafenib or tipiracil hydrochloride monotherapy. Further investigation of similar combinations is warranted. ClinicalTrials.gov identifier NCT02393755

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineIndolesProgression-Free SurvivalColorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultFatigueHand-Foot SyndromeAged, 80 and overDrug Resistance, NeoplasmBilirubin

Substanzen

nintedanibCapecitabineIndolesBilirubin

Autor:innen und Institutionen

  • Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.

ORCID-Profile: Patrick M Boland, Marwan Fakih

Förderung

  • National Comprehensive Cancer Network
  • Boehringer Ingelheim

Zitieren

APA

Boland, P. M., Ebos, J. M. L., Attwood, K., Mastri, M., Fountzilas, C., Iyer, R. V., Banker, C., Goey, A. K. L., Bies, R., Ma, W. W., & Fakih, M. (2024). A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer. JNCI Cancer Spectrum, 8(3). https://doi.org/10.1093/jncics/pkae017

Vancouver

Boland PM, Ebos JML, Attwood K, Mastri M, Fountzilas C, Iyer RV, et al. A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer. JNCI Cancer Spectrum. 2024;8(3). doi:10.1093/jncics/pkae017

BibTeX
@article{Boland2024,
  author = {Boland, Patrick M and Ebos, John M L and Attwood, Kristopher and Mastri, Michalis and Fountzilas, Christos and Iyer, Renuka V and Banker, Christopher and Goey, Andrew K L and Bies, Robert and Ma, Wen Wee and Fakih, Marwan},
  title = {A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  volume = {8},
  number = {3},
  doi = {10.1093/jncics/pkae017}
}
Kostenlos starten →